EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer

Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang

The Journal of Applied Laboratory Medicine · 03.01.2024 · 9 (1) · 76-91

DOI: 10.1093/jalm/jfad091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 03.01.2024. Verfasst von Melissa Yuwono Tjota und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Chicago, Chicago, IL 60637, United States. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 125 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Comprehensive genomic profiling (CGP) with next-generation sequencing detects genetic alterations of hundreds of genes simultaneously and multiple molecular biomarkers with one test. In the personalized medicine era, CGP is increasingly used for cancer diagnosis, treatment selection, and prognosis prediction. Content In this review, we summarize the benefits of CGP, clinical utility of CGP, and challenges of setting up CGP in the clinical laboratories. Besides the genetic alterations identified in the cancer-related genes, other biomarkers such as tumor mutational burden, microsatellite instability, and homologous recombination deficiency are critical for initiating targeted therapy. Compared with conventional tests, CGP uses less specimen and shortens the turnaround time if multiple biomarkers need to be tested. RNA fusion assay and liquid biopsy are helpful additions to DNA-based CGP by detecting fusions/splicing variants and complementing tissue-based CGP findings, respectively. Summary Many previous hurdles for implementing CGP in the clinical laboratories have been gradually alleviated such as the decrease in sequencing cost, availability of both open-source and commercial bioinformatics tools, and improved reimbursement. These changes have helped to make CGP available to a greater population of cancer patients for improving characterization of their tumors and expanding their eligibility for clinical trials. Additionally, sequencing results of the hundreds of genes on CGP panels could be further analyzed to better understand the biology of various cancers and identify new biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansMutationPrognosisBiomarkers, TumorGenomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, The University of Chicago, Chicago, IL 60637, United States.

Zitieren

APA

Tjota, M. Y., Segal, J. P., & Wang, P. (2024). Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer. The Journal of Applied Laboratory Medicine, 9(1), 76-91. https://doi.org/10.1093/jalm/jfad091

Vancouver

Tjota MY, Segal JP, Wang P. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer. The Journal of Applied Laboratory Medicine. 2024;9(1):76-91. doi:10.1093/jalm/jfad091

BibTeX
@article{Tjota2024,
  author = {Tjota, Melissa Yuwono and Segal, Jeremy P and Wang, Peng},
  title = {Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2024},
  volume = {9},
  number = {1},
  pages = {76--91},
  doi = {10.1093/jalm/jfad091}
}
Kostenlos starten →